It is known that the number of transplanted cells has a significant impact on the outcome after SCT. We identify issues that cannot be addressed by conventional analysis of clinical trials and ask whether it is possible to develop a refined analysis to conclude about the outcome of individual patients given clinical trial results. To accomplish this, we propose an interdisciplinary approach based on mathematical modeling. We devise and calibrate a mathematical model of short-term reconstitution and simulate treatment of large patient groups with random interindividual variation. Relating model simulations to clinical data allows quantifying the effect of transplant size on reconstitution time in the terms of patient populations and individual patients. The model confirms the existence of lower bounds on cell dose necessary for secure and efficient reconstitution but suggests that for some patient subpopulations higher thresholds might be appropriate. Simulations demonstrate that relative time gain because of increased cell dose is an 'interpersonally stable' parameter, in other words that slowly engrafting patients profit more from transplant enlargements than average cases. We propose a simple mathematical formula to approximate the effect of changes of transplant size on reconstitution time.
INTRODUCTION
Hematopoietic SCT is a well-established clinical procedure. 1 Clinical trials have confirmed the impact of transplant size on fast and sustained engraftment. 2 Accordingly, lower bounds on the number of transplanted cells have been defined to ensure safe treatment. Nevertheless, individual engraftment times differ widely and delayed engraftment occurs. [3] [4] [5] The time before neutrophil reconstitution is clinically meaningful for various reasons: (i) infections during neutropenia account for a considerable number of complications and deaths, [6] [7] [8] [9] especially in cord blood transplantations. [10] [11] [12] [13] (ii) Several studies propose an association between rapid neutrophil recovery and long-term engraftment 14 or high marrow donor chimerism. 15 (iii) In some trials, transplant-related mortality or poor long-term outcome are associated with delayed neutrophil engraftment. [16] [17] [18] In almost every trial, there exist patients with recovery times distant from average. The dose of transplanted cells has an impact on the time to neutrophil reconstitution 2, 19 and is a tunable parameter; therefore, it is important to know whether slowly reconstituting patients might benefit from increased numbers of transplanted cells. As such patients cannot be identified before transplantation, it is difficult to apply prospective clinical trials. Therefore, it remains unknown how much these patients might profit from increased numbers of transplanted cells.
As SCT can only be performed once at a given time for a given patient, direct comparison of effects of different modifications for a given individual is not possible. In practice, this problem is circumvented by the comparison of randomized study groups. This approach gives an idea of the average impact of different modifications on clinical outcome, but fails to provide a measure of benefit to individuals. It cannot be ruled out that some subpopulations benefit stronger from an intervention than averaged data suggest, whereas others may show worse, maybe critical outcome, although average outcome improves. Figure 1 demonstrates that subpopulations of trial groups may react differently to different treatment interventions even if the aggregate outcome for the different interventions does not differ significantly. Only if aggregate data reflect individual responses, it is possible to directly apply trial results to individuals. Unlike clinical trials, simulations allow to compare different treatments for the same individual. Using mathematical modeling, we focus on the dependence of reconstitution time on transplanted cell dose.
Another methodology to compare the impact of different interventions is the case-control approach. This requires matching of different patients with respect to traits possibly influencing the outcome. However, in the considered case, such traits have not yet been established.
In this manuscript, we address the question how aggregate data from clinical trials on reconstitution after SCT can be interpreted on the level of individuals and, based on this, whether outcome for slowly reconstituting patients could be improved by increasing the transplanted cell numbers. We also ask how clinical recommendations concerning the minimal number of transplanted cells apply to individual patients. To take into account effects of cell source and conditioning, we investigate the impact of higher transplant doses on neutrophil engraftment separately for all common modes of SCT, viz the autologous, allogeneic or cord blood stem cells, in presence or absence of cytokine administration, and myeloablative vs reduced intensity conditioning.
So far such aspects were not approached using mathematical modeling. The existing models of healthy hematopoiesis are either mostly phenomenological [20] [21] [22] [23] [24] or solely based on regulation in the stem cell pool [24] [25] [26] and do not describe regulation of the whole system of differentiating cells. The latter is crucial for reconstitution after large perturbations and for quantitative analysis of post transplant dynamics.
Our reasoning is as follows. We devise a mathematical model for neutrophil reconstitution after SCT of single patients. The model is calibrated based on patient data and on measurements found in literature. As reconstitution kinetics differ among individuals, we investigate large groups of heterogeneous patients to consider a wide spectrum of individual responses and to compare them with aggregate data. Estimation of individual response based on aggregate data also requires the simulation of large patient groups that resemble the populations of clinical trials. We therefore apply the model to groups of patients with random interindividual differences and validate this approach based on data from clinical trials. On the basis of simulations of patient groups, we show that absolute reduction of reconstitution times due to a fixed additional amount of transplanted cells differs strongly between individuals, whereas relative reduction is approximately conserved and equals the relative reduction of average reconstitution times determined in clinical trials. We provide a formula to approximate this effect and conclude that patients prone to delayed engraftment benefit stronger from larger transplants than patients with average reconstitution times.
MATERIALS AND METHODS
We first summarize clinical trial data used for this work. Then we formulate our mathematical model and calibrate it based on a literature review and on a comparison to patient data. Having shown that model behavior is in agreement with clinical observations, we apply it to estimate individual treatment responses. Table 1 contains a listing of literature sources used to calibrate the model. As various diseases are treated by PBSC transplantations (PBSCT), we focus on trial data including different diagnoses. We consider the following scenarios used in current clinical practice: autologous PBSCT with and without post transplant cytokine administration, 19, 27 HLA-identical allogeneic PBSCT with 28, 29 and without 30, 31 post transplant cytokine administration, haplo-identical PBSCT 32, 33 and umbilical cord blood transplantation. 34 We also consider the impact of reduced conditioning regimens. 35 To compare simulations of leukocyte counts after autologous PBSCT with patient data, we use single patient data of one arm (containing patients treated with selected PBSCs) of the trial from. 19 For this task, we obtained original data of representative patients from Klaus et al. 19 
Clinical data

Mathematical model
The model is a modification of the model developed by Marciniak-Czochra and colleagues. [36] [37] [38] Unlike in the models of Marciniak-Czochra and colleagues, [36] [37] [38] proliferation rate in the present model is cytokine dependent only for primitive cells, as suggested by experiments in Thornley et al. 39 Model structure is presented in Figure 2 . Mathematical equations are found in Supplementary Methods (section 1) and in Supplementary Figure 1 .
We assume that mature blood cells are maintained by a population of hematopoietic stem cells and that there exists a finite number of maturation stages. This structure is accepted in clinical practice. 40 As leukopenia is responsible for most severe complications during aplasia, we only consider leukopoiesis. As neutrophils constitute the majority of peripheral WBC, the model is limited to granulopoiesis. The maturation stages considered include stem cells, different CFUs, different granulopoietic precursors and mature cells; they have been chosen based on an extensive literature search (see Supplementary Methods, We compare an intervention group of 1000 randomly chosen people to an independent control group of 1000 randomly chosen people. The end point, for example, time to recovery from a disease, is indicated on the vertical axis. We assume a normal distribution with mean 15 and s.d. 2 for the control group. The control group is displayed in E. The time of recovery that a patient needs without an intervention is referred to as the intrinsic time of recovery. Although aggregate data sets in A-D look practically identical and do not differ significantly (P ¼ 0.781 in Kruskal-Wallis test), the outcome at the level of individuals can be considerably different. In A, time of recovery of each individual patient is reduced by 10% because of the intervention. In this case, the change of average values corresponds to changes on the individual level. In B, patients with intrinsic long recovery times, above 19 days, benefit stronger, their recovery time is reduced by 20%. In C, the intervention is disadvantageous for 50% of patients with intrinsically long recovery times, above 19 days. Their recovery is delayed randomly between 0 and 50%, whereas all other patients benefit from a 10% reduction of their intrinsic recovery time. Although mean values improve, the intervention is in this case dangerous for the critical group of patients with long intrinsic recovery times. In D, the intervention leads to a 10% reduction of intrinsic recovery times between 13 and 17 days. Intrinsic recovery times of o13 days are delayed by 30% because of the intervention and intrinsic recovery times of 417 days are reduced by 40%. In this case, the intervention is beneficial for some patients and disadvantageous for others. The average over data suggests an improvement because of the intervention, although this is not the case for 415% of treated patients. The examples demonstrate that aggregate data are not suitable for drawing conclusions at the level of individuals. Although study outcome is identical in cases A-D, in cases B and D it would be helpful to develop a screening procedure that may distinguish between patients that benefit from the intervention and those who do not, whereas in case A, this is not necessary. Panel (b) depicts the outcome of each intervention applied to three different groups of 100 patients. In this case, statistical variability further confuses the outcome. Boxes show the 25th-75th percentile, whiskers denote 97.5 and 2.5 percentiles, values beyond the whiskers are depicted as circles, median values are indicated as horizontal lines.
Engraftment after SCT T Stiehl et al section 1.21). Cell dynamics are determined by proliferation, differentiation and death. Each of the progeny cells arising from division either remains in the same maturation stage as the parent cell, which is referred to as selfrenewal, or progresses to the subsequent more mature stage, which is referred to as differentiation. We assume that the proliferation of all cell types is regulated by cytokines, such as G-CSF and that the fraction of selfrenewal depends on cytokine levels. We conclude that our model can be applied to simulate clinical data, as (i) simulated steady state population sizes, generation times and granulocyte half-life are in good agreement with data from literature; see Supplementary Tables 4 and 5 Figure 2) . This is in line with telomere studies 42 and demonstrates independence of shortterm reconstitution of primitive cell parameters.
Simulation of large patient groups
For simulation of large patient groups, we generate random perturbation of cell parameters; see Supplementary Methods (section 3). Comparison with data is shown in Figure 4 and Supplementary Figure 3 .
To study the impact of transplanted cell dose on individual engraftment, we consider absolute and relative gain of reconstitution time. Absolute gain describes by how many days the reconstitution is reduced if the transplanted cell dose is increased. Relative gain expresses the gain in percent. Both indices can be calculated using averaged data from clinical trials. We use this averaged absolute and relative time gains as candidate predictors for individual time gains. To compare both modes of prediction, we simulate clinical trials and compare for each virtual patient the 'effective' (simulated) gain with the gain predicted by average absolute or relative changes obtained from clinical trials. For details see Supplementary Methods (section 4). Â 100% % 6% ffi 1 day.
Relative gain of reconstitution time is conserved among individuals To estimate how increased transplant sizes improve outcome of extremely slowly reconstituting patients, we repeated the simulations for different groups of patients: group 1, o20 days for 3 Â 10 6 cells per kg; group 2, 20-30 days; and group 3 430 days. Simulation results show that relative time gain is similar for patients with average and with short reconstitution times; see Supplementary Figure 4 . This implies that the absolute time gain is larger for slowly reconstituting patients.
Transplant enlargement above the clinically established threshold might have impact on recovery times of slowly reconstituting patients The relative reduction of the reconstitution time because of X additional CD34 þ cells is calculated using the formula (1), with C ¼ À 8.4 ± 0.71. For the subpopulation of patients with reconstitution times between 20 and 30 days, we obtain C ¼ À 8.1 ± 1.1. Above, we calculated the impact of adding 10 6 CD34 þ cells to a transplant of 3 Â 10 6 cells, which was 6%. In case of average patients with reconstitution times between 15 and 20 days, this leads to reduction by B1 day. In case of a slowly reconstituting patient with reconstitution time of 30 days, this leads to a reduction by 1 À log 10 ð4Â10
6 Þ À 8:1 log 10 ð3Â10 6 Þ À 8:1 Â 100% % 8% ffi 2:4 days, that is, the gain is more than twofold. If we increase dose from 2 Â 10 6 to 1.5 Â 10 7 CD34 þ cells per kg of body weight, we obtain an estimated reduction of reconstitution time of 1 À log 10 ð1:5Â10 7 Þ À 8:1 log 10 ð2Â10 6 Þ À 8:1 Â 100% % 47% for this group.
Relative change of neutrophil reconstitution time from clinical trials reflects individual patient's response It is an important question how data from clinical trials can be optimally used to estimate treatment response of individual patients. We use the in silico approach to tackle this question. Clinical trials usually record average reconstitution times for different ranges of transplant size. We compare two algorithms of estimating reduction of individual hematopoietic reconstitution using these data: (1) absolute reduction of reconstitution time of an individual due to an additional fixed amount of cells is estimated by absolute reduction of average reconstitution time of a large group of patients and (2) relative reduction of reconstitution time of an individual is estimated by the relative reduction of average reconstitution time of a large group of patients. Differences between simulated and estimated changes are shown in Supplementary Figure 5 . The s.d. of the difference between predicted and effective values, which is a measure of the number of predictions that strongly deviate from effective values, is up to 2.5 times larger if predictions are based on absolute differences. This implies that it is more appropriate to use the relative change of average reconstitution times to estimate the individual benefit. We now consider the subpopulation that needs 20 days or more to engraft after transplantation of 3 Â 10 6 CD34 þ per kg of body weight. We want to estimate how reconstitution time decreases if we increase cell dose from 3 Â 10 6 per kg to 10 7 per kg. Estimation based on average absolute difference obtained from days. This demonstrates that the average relative time gain is a better measure of individual time gain and is accurately conserved between different patient subpopulations, whereas the use of average absolute time gains may underestimate benefits for slowly engrafting patients. In summary, relative change in reconstitution time is a better measure of benefit as it is conserved over different patients and can be estimated by average relative change of aggregate data. Individual relative change is approximately equal to the relative change of averaged values from large patient groups.
DISCUSSION
We developed and validated a mathematical model of short-term neutrophil reconstitution after different kinds of SCTs. This approach allows quantifying effects that are not estimable via conventional statistical analysis of clinical trials and that cannot be concluded from aggregate data. The in silico approach offers the possibility of directly comparing different interventions for the same virtual patient.
The combination of mathematical modeling and clinical trial data leads to new quantitative and qualitative insights into medical treatment procedures. The proposed model implies that relative change in reconstitution time because of enlargement of transplant (i.e., increase in CD34 þ cell dose) is an interpersonally stable parameter decreasing with increasing transplant size. This parameter can be estimated from clinical trial data. The finding implies that the absolute time gain because of additionally transplanted cells is larger in slowly reconstituting patients who, accordingly, could profit from higher counts of transplanted cells in clinical practice. We propose a simple formula that allows estimating this effect for cell doses up to about 5 Â 10 7 CD34 þ cells per kg of body weight. Our study confirms, at the individual patient level, the existence of a lower bound on cell dose for successful transplantation, which is 2-3 Â 10 6 cells per kg in clinical practice 2, 43 and has been derived from clinical trials. Our results support the finding that for average patients transplant sizes above this threshold have little impact, 2,43 but they underline that this may not be the case for slowly reconstituting patients.
The absolute reconstitution time may differ strongly among individuals. The model suggests that these variations stem from interindividual differences in parameters of hematopoiesis. Thus, a precise prediction of absolute reconstitution time is not possible. The results presented hold across different types of SCTs and conditioning regimens.
We use model parameters with a biological interpretation; however, some of the values are not known accurately. For this reason, we chose random sets of model parameters to simulate large patient groups. Further research could include explicit incorporation of immunological mechanisms and the impact of the microenvironment as soon as data on these subjects are available.
The finding that relative change in reconstitution time is nearly conserved between patients is new and cannot be concluded from clinical data. Clinically relevant results of this work are (i) when interpreting trial results, it should be taken into account that not absolute but relative changes of reconstitution time because of different cell doses are similar for all patients. (ii) Patients at risk for delayed reconstitution might profit remarkably from enlarged transplants. This raises the question as to whether more careful patient triage and risk-adjusted lower bounds of transplant size could be helpful in clinical practice. This has to be a subject of further research. Up to now, several risk factors for delayed engraftment have been identified, including HHV6 infection, 44 gene polymorphisms, 45 splenomegaly 46,47 and others. 3, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] The current results underline that further investigation of this topic Figure 4 . Calibration of the model to different clinical scenarios: (a) autologous PBSC with and without post transplant cytokine administration; patient data taken from Lowenthal et al. 27 (b) Allogeneic HLA-identical PBSC without post transplant cytokine administration; patient data taken from trials by Vigorito et al. 30 and Bensinger et al. 31 (c) Allogeneic HLA-identical PBSC with post transplant cytokine administration; patient data taken from different trials. [28] [29] (d) Allogeneic HLA-haplo-identical PBSC with and without post transplant cytokine administration; patient data taken from trials by Aversa et al. 32 and Kato et al. 33 Model has been scaled to the fraction of patients alive and engrafted after 40 days. (e) Transplantation of umbilical cord blood; patient data taken from Rubinstein et al. 34 Model has been scaled to the fraction of patients alive and engrafted after 100 days. (f ) Allogeneic PBSC after reduced intensity conditioning; data taken from Chunduri et al. and individual adaptation of lower cell bounds may improve the outcome after SCTs.
